Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 15,824 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study Product Clear all

Conditions: Substance Abuse
Interventions: drug prevention curriculum; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 14 Years to 19 Years
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Contraception
Interventions: AG200-15 (cycles 1-13), Lessina crossover to AG200-15; Drug
Lead sponsor: Agile Therapeutics; Industry
Eligibility: 17 Years to 40 Years · Female only
Enrollment: 1,504 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 80
States / cities: Huntsville, Alabama • Mobile, Alabama • Chandler, Arizona + 77 more

Conditions: Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult, Metastatic Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer
Interventions: vobramitamab duocarmazine; Biological
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 9
States / cities: Santa Monica, California • Washington D.C., District of Columbia • Baltimore, Maryland + 5 more

Conditions: Intraocular Melanoma, Melanoma (Skin), Metastatic Cancer
Interventions: melphalan, regional chemotherapy, systemic chemotherapy, hepatic artery embolization; Drug · Procedure
Lead sponsor: Delcath Systems Inc.; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 12
States / cities: Santa Monica, California • Englewood, Colorado • Tampa, Florida + 9 more

Conditions: Heart Septal Defects, Ventricular, Atrioventricular Septal Defect
Interventions: IV L-carnitine; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 2 Months to 12 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Advanced Malignancies
Interventions: MBG453, PDR001, Decitabine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 4
States / cities: Baltimore, Maryland • Boston, Massachusetts • Houston, Texas + 1 more

Conditions: Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Lung Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Neuroendocrine Carcinoma, Unresectable Pancreatic Adenocarcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Elimusertib, Irinotecan Hydrochloride, Magnetic Resonance Imaging, Topotecan Hydrochloride; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 23
States / cities: Phoenix, Arizona • Orange, California • New Haven, Connecticut + 17 more

Conditions: Kidney Diseases
Interventions: Renasight; Diagnostic Test
Lead sponsor: Natera, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 31
States / cities: Anchorage, Alaska • Tucson, Arizona • Granada Hills, California + 23 more

Conditions: Alzheimer Disease, Dementia, Mild, Mild Cognitive Impairment
Interventions: Electroencephalogram (EEG) system, Standard Neuropsychological Testing, Additional neuropsychological tests; Device · Behavioral
Lead sponsor: Boston University; Other
Eligibility: 20 Years to 90 Years
Enrollment: 148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Normal Athletes
Interventions: L Max, Placebo; Other
Lead sponsor: Climatic, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy
Interventions: Ramipril10 mg Capsules, single dose, Atlace® 10 mg capsules, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Low Milk Supply, Pre-diabetes, Insulin Resistance, Suppressed Lactation
Interventions: Standard care, Metformin, Placebo; Behavioral · Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 20 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hyperlipidemias
Interventions: Lapaquistat acetate and fenofibrate, Fenofibrate; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 32
States / cities: Huntsville, Alabama • Sierra Vista, Arizona • Beverly Hills, California + 29 more

Conditions: Ileostomy - Stoma
Interventions: Teduglutide, Placebo; Drug
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Ebola Virus Disease
Interventions: Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP), Deuterium Labeled Water; Biological · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Decatur, Georgia • St Louis, Missouri

Conditions: Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Ixazomib Citrate, Lenalidomide, Placebo Administration, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 221
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Arroyo Grande, California + 154 more

Conditions: Asthma
Interventions: GW685698X, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 599 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 94
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 81 more

Conditions: Pain, Postoperative
Interventions: liposomal bupivicaine; Drug
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: San Diego, California

Conditions: Healthy, Obese
Interventions: Tadalafil, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 21 Years to 50 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Dietary Supplements
Interventions: Emergen-C Core Super Orange Powder, Placebo; Dietary Supplement
Lead sponsor: HALEON; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 299 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Pharmacokinetics, Pharmacodynamics, Insulin Aspart
Interventions: I004, NovoLog; Drug
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Advanced Solid Tumor
Interventions: SGN1; Drug
Lead sponsor: Guangzhou Sinogen Pharmaceutical Co., Ltd; Other
Eligibility: 18 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Gilbert, Arizona • Orange, California • Detroit, Michigan + 1 more

Conditions: Facial Hyperpigmentation
Interventions: Test cosmetic product; Drug
Lead sponsor: Kayuraeffect, LLP; Industry
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 2
States / cities: Miami Lakes, Florida • New York, New York

Conditions: Peripheral Neuropathy, Type 1 Diabetes
Interventions: Salsalate; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Youth Substance Use Prevention/Reduction Through Science-based Drug Abuse Education

Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System

MGC018 With or Without MGA012 in Advanced Solid Tumors

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

Aberrations in Carnitine Homeostasis in Congenital Heart Disease With Increased Pulmonary Blood Flow

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Renasight Clinical Application, Review and Evaluation (RenaCARE) Study

Event-Related Potential (ERP) Components in Clinical Diagnosis

A Randomized, Placebo Controlled Trial of L Max in Healthy Adult Athletes

A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fed Conditions

Metformin to Augment Low Milk Supply (MALMS) Study

Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels

Pilot Study to Investigate the Effect of Teduglutide on Temporary Ileostomy Function and Complications

Immunology of Ebola Vaccine

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.

Trial of Liposomal Versus Plain Bupivacaine in Minimally Invasive General Surgery Procedures

PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction

A Study Evaluating Quality of Life Parameters Following Use of Emergen-C

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers

Study of SGN1 in Patients With Advanced Solid Tumor

Open-label, Single-arm, Proof of Concept Study in Subjects with Mild-to-moderate Facial Hyperpigmentation

Pilot Study to Determine Effects of Salsalate in Type 1 Diabetes and Painful Peripheral Neuropathy